Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC trimmed its stake in shares of Inari Medical, Inc. (NASDAQ:NARI – Get Rating) by 2.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,841 shares of the company’s stock after selling 570 shares during the period. Janney Montgomery Scott LLC’s holdings in Inari Medical were worth $1,659,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Texas Permanent School Fund acquired a new stake in Inari Medical during the second quarter worth about $1,671,000. State of New Jersey Common Pension Fund D acquired a new stake in Inari Medical during the second quarter worth about $2,652,000. Renaissance Technologies LLC grew its holdings in Inari Medical by 105.6% in the second quarter. Renaissance Technologies LLC now owns 194,299 shares of the company’s stock valued at $13,210,000 after purchasing an additional 99,800 shares during the period. Strs Ohio grew its holdings in Inari Medical by 23.3% in the second quarter. Strs Ohio now owns 5,300 shares of the company’s stock valued at $360,000 after purchasing an additional 1,000 shares during the period. Finally, Brown Advisory Inc. grew its holdings in Inari Medical by 54.9% in the second quarter. Brown Advisory Inc. now owns 1,075,189 shares of the company’s stock valued at $73,197,000 after purchasing an additional 380,961 shares during the period. 85.19% of the stock is owned by institutional investors and hedge funds.

Inari Medical Stock Up 1.8 %

Shares of NARI opened at $67.05 on Monday. Inari Medical, Inc. has a 52-week low of $50.50 and a 52-week high of $100.00. The company has a market capitalization of $3.60 billion, a PE ratio of -159.64 and a beta of 1.21. The stock has a fifty day simple moving average of $70.17 and a two-hundred day simple moving average of $72.73.

Inari Medical (NASDAQ:NARI – Get Rating) last issued its earnings results on Wednesday, November 2nd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.05. Inari Medical had a negative return on equity of 6.02% and a negative net margin of 6.23%. The business had revenue of $96.20 million during the quarter, compared to the consensus estimate of $90.65 million. As a group, equities analysts anticipate that Inari Medical, Inc. will post -0.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on NARI shares. Truist Financial dropped their price objective on Inari Medical from $84.00 to $75.00 and set a “hold” rating on the stock in a report on Tuesday, December 20th. Jefferies Financial Group started coverage on Inari Medical in a report on Wednesday, October 12th. They issued a “buy” rating and a $88.00 price objective on the stock. Morgan Stanley dropped their price objective on Inari Medical from $95.00 to $83.00 and set an “overweight” rating on the stock in a report on Friday, January 6th. BTIG Research decreased their target price on Inari Medical from $100.00 to $97.00 and set a “buy” rating on the stock in a research report on Monday, October 17th. Finally, Wells Fargo & Company dropped their price target on Inari Medical from $125.00 to $105.00 in a research report on Thursday, November 3rd. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.60.

Insiders Place Their Bets

In other Inari Medical news, Director Donald B. Milder sold 7,000 shares of the firm’s stock in a transaction on Tuesday, October 18th. The stock was sold at an average price of $80.07, for a total value of $560,490.00. Following the completion of the sale, the director now directly owns 3,192,614 shares of the company’s stock, valued at approximately $255,632,602.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Donald B. Milder sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of $80.07, for a total transaction of $560,490.00. Following the completion of the sale, the director now directly owns 3,192,614 shares of the company’s stock, valued at approximately $255,632,602.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Hoffman sold 55,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $81.67, for a total value of $4,491,850.00. Following the sale, the chief executive officer now directly owns 237,481 shares of the company’s stock, valued at $19,395,073.27. The disclosure for this sale can be found here. Insiders sold 219,250 shares of company stock valued at $16,112,973 in the last three months. 11.90% of the stock is currently owned by insiders.

Inari Medical Profile

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.